The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial

PURPOSE: The clinical impact of concurrent corticosteroid use (CCU) on enzalutamide-treated patients with metastatic castration-resistant prostate cancer (mCRPC) is unknown. We investigated the association of CCU with overall survival (OS), radiographic progression-free survival (rPFS), and time to...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jimmy L., Fizazi, Karim, Saad, Fred, Chi, Kim N., Taplin, Mary-Ellen, Sternberg, Cora N., Armstrong, Andrew J., de Bono, Johann S., Duggan, William T., Scher, Howard I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366341/
https://www.ncbi.nlm.nih.gov/pubmed/34965947
http://dx.doi.org/10.1158/1078-0432.CCR-21-1090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9366341/
https://www.ncbi.nlm.nih.gov/pubmed/34965947
http://dx.doi.org/10.1158/1078-0432.CCR-21-1090

Ejemplares similares